Drugs regulating PPARγ provide a potential interventional target in COPD; rosiglitazone was reported to inhibit cigarette smoke‐induced pulmonary inflammation44 and reduce exacerbations by attenuating pulmonary inflammation and decreasing bacterial burdens,45 suggesting PPARγ may therefore be an effective approach in treating COPD. This evidence concerns the gene PPARG and chronic obstructive pulmonary disease.